In re Generic Pharmaceuticals Pricing Antitrust Litigation
Nov, 2024
In re Generic Pharmaceuticals Pricing Antitrust Litigation (E.D. Pa.)
This antitrust litigation alleges that dozens of generic drug manufacturers have been colluding for over a decade to reduce competition and fix prices for more than 100 generic drugs, resulting in skyrocketing prices for generic drugs, some by as much as 8,000%. NastLaw is sole lead counsel for the class of direct purchasers of those drugs. The class entered into settlements with certain Defendants and continues to litigate claims against other Defendants. Please refer to the settlement website (https://genericdrugsdirectpurchasersettlement.com/) for further information.